Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

2017 NCCN Annual Conference

Suzanne George, MD, of Dana-Farber Cancer Institute, discusses current and emerging systemic therapies for soft-tissue sarcoma and the options for multimodality treatment.

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Margaret A. Tempero, MD, of the UCSF Helen ...

Bladder Cancer

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

Elizabeth R. Plimack, MD, of Fox Chase Canc...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Ket...

Lymphoma

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Leo I. Gordon, MD, of the Robert H. Lurie C...

Jun

Today In Oncology

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Related Videos

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Margaret A. Tempero, MD, on Pancreatic Cancer: Active Systemic Treatment

Elizabeth R. Plimack, MD, on Bladder Cancer: Management Updates

David G. Pfister, MD, on HPV and Head and Neck Cancer

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

First-Line Atezolizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer

Cediranib/Olaparib vs Standard of Care Chemotherapy for Platinum-Sensitive Ovarian Cancer

Remote Pre- and Post-Test Genetic Counseling for Breast and Ovarian Cancer Risk

Standard vs Histology-Tailored Neoadjuvant Chemotherapy for High-Risk Soft Tissue Sarcoma

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma